Breaking Medical Technology
News: Aethlon Medical (NASDAQ: $AEMD) to Release Fiscal First Quarter Financial
Results and Host Conference Call on August 14, 2024
SAN
DIEGO - August 6, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing
products to treat cancer and life threatening infectious diseases, today
announced that it will issue financial results for its fiscal first quarter
ended June 30, 2024, at 4:15 p.m. ET on Wednesday, August 14, 2024.
Management will host a conference call
on Wednesday, August 14, 2024, at 4:30 p.m. ET to review financial results and
recent corporate developments. Following management's formal remarks, there
will be a question and answer session.
Interested parties can register for
the conference by navigating to https://dpregister.com/sreg/10191735/fd44630e3d.
Please note that registered participants will receive their dial-in number upon
registration.
Interested parties without internet
access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE):
1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the
Aethlon Medical, Inc. conference call.
A replay of the call will be available
approximately one hour after the end of the call through September 14, 2024.
The replay can be accessed via Aethlon Medical's website or by dialing
1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free
at 1-855-669-9658. The replay conference ID number is 3788019.
This news is paid advertisement/ news disseminated
on behalf of/issued on behalf of Aethlon Medical Inc.
Read this news, featuring AEMD in full at https://www.investorideas.com/news/2024/08061AEMD-Q2-Financial-Results-Conferece-Call.asp
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical
therapeutic company focused on developing the Hemopurifier, a clinical stage
immunotherapeutic device which is designed to combat cancer and
life-threatening viral infections and for use in organ transplantation. In
human studies, the Hemopurifier has demonstrated the removal of
life-threatening viruses and in pre-clinical studies, the Hemopurifier has
demonstrated the removal of harmful exosomes from biological fluids, utilizing
its proprietary lectin-based technology. This action has potential applications
in cancer, where exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug
Administration (FDA) designated Breakthrough Device indicated for the treatment
of individuals with advanced or metastatic cancer who are either unresponsive
to or intolerant of standard of care therapy, and with cancer types in which
exosomes have been shown to participate in the development or severity of the
disease. The Hemopurifier also holds an FDA Breakthrough Device designation and
an open Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with approved
therapies.
Additional information can be found
at www.AethlonMedical.com.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve
risks and uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect,"
"intend," "plan," "project," "will,"
"projections," "estimate," "potentially" or
similar expressions constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and actual
results may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are based upon
Aethlon's current expectations and involve assumptions that may never
materialize or may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's ability to raise
additional capital and to successfully complete development of the
Hemopurifier; the Company's ability to successfully demonstrate the utility of
the Hemopurifier in cancer and infectious diseases and in the transplant
setting; the Company's ability to achieve and realize the anticipated benefits
from potential milestones; the Company's ability to submit applications to and
obtain approval from the additional Ethics Committees in Australia and India,
including on the timing expected by the Company; the Company's ability to
initiate its planned oncology clinical trials in Australia and India, including
on the timing expected by the Company; the Company's ability to manage and
successfully complete its clinical trials, if initiated; the potential impact
of Hemopurifier on the H5N1 Avian Influenza (H5N1 HPAI) virus in dairy cattle;
the Company's ability to successfully manufacture the Hemopurifier in
sufficient quantities for its clinical trials, and other potential risks. The
foregoing list of risks and uncertainties is illustrative, but is not
exhaustive. Additional factors that could cause results to differ materially
from those anticipated in forward-looking statements can be found under the
caption "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended March 31, 2024, and in the Company's other filings with the
Securities and Exchange Commission, including its quarterly Reports on Form
10-Q. All forward-looking statements contained in this press release speak only
as of the date on which they were made. Except as may be required by law, the
Company does not intend, nor does it undertake any duty, to update this
information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
Aethlon
Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com
More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/
Get News
Alerts on Aethlon Medical
Disclaimer/Disclosure: Investorideas.com
is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid
featured stock on Investorideas.com More disclaimer info: https://www.investorideas.com/About/News/Clientspecifics.asp https://www.investorideas.com/About/Disclaimer.asp
Learn more about publishing your news release and
our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Biotech Industry Stocks- investing ideas
in biotechnology stocks, medical technology and life sciences
